179 related articles for article (PubMed ID: 36386477)
1. A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer.
Li Y; Chu Y; Shi G; Wang X; Ye W; Shan C; Wang D; Zhang D; He W; Jiang J; Ma S; Han Y; Zhao Z; Du S; Chen Z; Li Z; Yang Y; Wang C; Xu X; Wu H
Acta Pharm Sin B; 2022 Nov; 12(11):4165-4179. PubMed ID: 36386477
[TBL] [Abstract][Full Text] [Related]
2. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.
Liang J; Wang L; Poluben L; Nouri M; Arai S; Xie L; Voznesensky OS; Cato L; Yuan X; Russo JW; Long HW; Brown M; Chen S; Balk SP
Cancer Lett; 2021 Oct; 519():172-184. PubMed ID: 34256096
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer.
Marín-Aguilera M; Jiménez N; Reig Ò; Montalbo R; Verma AK; Castellano G; Mengual L; Victoria I; Pereira MV; Milà-Guasch M; García-Recio S; Benítez-Ribas D; Cabezón R; González A; Juan M; Prat A; Mellado B
Cells; 2020 Jan; 9(1):. PubMed ID: 31947623
[TBL] [Abstract][Full Text] [Related]
6. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
Cato L; de Tribolet-Hardy J; Lee I; Rottenberg JT; Coleman I; Melchers D; Houtman R; Xiao T; Li W; Uo T; Sun S; Kuznik NC; Göppert B; Ozgun F; van Royen ME; Houtsmuller AB; Vadhi R; Rao PK; Li L; Balk SP; Den RB; Trock BJ; Karnes RJ; Jenkins RB; Klein EA; Davicioni E; Gruhl FJ; Long HW; Liu XS; Cato ACB; Lack NA; Nelson PS; Plymate SR; Groner AC; Brown M
Cancer Cell; 2019 Mar; 35(3):401-413.e6. PubMed ID: 30773341
[TBL] [Abstract][Full Text] [Related]
7. Increased chromatin accessibility drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer.
Poluben L; Nouri M; Liang J; Varkaris A; Ersoy-Fazlioglu B; Voznesensky O; Lee II; Qiu X; Cato L; Seo JH; Freedman ML; Sowalsky AG; Lack NA; Corey E; Nelson PS; Brown M; Long HW; Balk SP; Russo JW
bioRxiv; 2024 Jan; ():. PubMed ID: 38260576
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation.
Xu H; Sun Y; Huang CP; You B; Ye D; Chang C
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235588
[TBL] [Abstract][Full Text] [Related]
9. Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial).
Hench IB; Cathomas R; Costa L; Fischer N; Gillessen S; Hench J; Hermanns T; Kremer E; Mingrone W; Mestre RP; Püschel H; Rothermundt C; Ruiz C; Tolnay M; Burg PV; Bubendorf L; Vlajnic T; Sakk SGFCCR
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31374981
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
[TBL] [Abstract][Full Text] [Related]
11. Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression.
Wu G; Sun Y; Xiang Z; Wang K; Liu B; Xiao G; Niu Y; Wu D; Chang C
Cell Death Dis; 2019 Jan; 10(2):37. PubMed ID: 30674872
[TBL] [Abstract][Full Text] [Related]
12. The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer.
Wang K; Luo J; Yeh S; You B; Meng J; Chang P; Niu Y; Li G; Lu C; Zhu Y; Antonarakis ES; Luo J; Huang CP; Xu W; Chang C
Nat Commun; 2020 Jun; 11(1):2689. PubMed ID: 32483206
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
14. The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer.
Zheng Z; Li J; Liu Y; Shi Z; Xuan Z; Yang K; Xu C; Bai Y; Fu M; Xiao Q; Sun H; Shao C
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230800
[TBL] [Abstract][Full Text] [Related]
15. DNA binding alters ARv7 dimer interactions.
Özgün F; Kaya Z; Morova T; Geverts B; Abraham TE; Houtsmuller AB; van Royen ME; Lack NA
J Cell Sci; 2021 Jul; 134(14):. PubMed ID: 34318896
[TBL] [Abstract][Full Text] [Related]
16. The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer.
Liu B; Sun Y; Tang M; Liang C; Huang CP; Niu Y; Wang Z; Chang C
Cell Death Dis; 2020 Sep; 11(9):807. PubMed ID: 32978369
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells.
Lin C; Chou FJ; Lu J; Lin W; Truong M; Tian H; Sun Y; Luo J; Yang R; Niu Y; Nadal R; Antonarakis ES; Cordon-Cardo C; Sahasrabudhe D; Huang CP; Yeh S; Li G; Chang C
Aging (Albany NY); 2020 Sep; 12(17):17694-17712. PubMed ID: 32920545
[TBL] [Abstract][Full Text] [Related]
18. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract][Full Text] [Related]
19. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.
Škereňová M; Mikulová V; Čapoun O; Švec D; Kološtová K; Soukup V; Honová H; Hanuš T; Zima T
Mol Diagn Ther; 2018 Jun; 22(3):381-390. PubMed ID: 29725990
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
